S-MEPHENYTOIN, SPARTEINE AND DEBRISOQUINE OXIDATION - GENETIC POLYMORPHISMS IN A TURKISH POPULATION

被引：13

作者：

BASCI, NE

BROSEN, K

BOZKURT, A

ISIMER, A

SAYAL, A

KAYAALP, SO

机构：

[1] ODENSE UNIV,INST MED BIOL,DEPT CLIN PHARMACOL,ODENSE,DENMARK

[2] GULHANE MIL MED ACAD,DEPT PHARMACOL,ANKARA,TURKEY

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1994年 / 38卷 / 05期

关键词：

MEPHENYTOIN; DEBRISOQUINE; SPARTEINE; GENETIC POLYMORPHISM; TURKISH POPULATION;

D O I：

10.1111/j.1365-2125.1994.tb04383.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

A mephenytoin test was carried out in 106 unrelated healthy Turkish volunteers. Racemic mephenytoin was coadministered with either debrisoquine or sparteine. The S/R mephenytoin ratio ranged from < 0.1 to 0.73 in 105 subjects, accordingly phenotyped as extensive metabolisers. One subject had an S/R mephenytoin ratio of 1.02, showing that he was a poor metaboliser of mephenytoin (0.94%, confidence interval 0.25% and 13.65%). In 48 subjects, the metabolic ratios of debrisoquine and sparteine were correlated significantly (r(s) = 0.61, P < 0.001).

引用

页码：463 / 465

页数：3

共 13 条

[1] HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS
ALVAN, G
BECHTEL, P
ISELIUS, L
GUNDERTREMY, U
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) : 533 - 537
[2] CORRELATION BETWEEN THE METABOLIC RATIOS OF DEBRISOQUINE AND METOPROLOL IN TURKISH SUBJECTS
BASCI, NE
BOZKURT, A
ISIMER, A
KAYAALP, SO
[J]. PHARMACOLOGY & TOXICOLOGY, 1994, 75 (01): : 62 - 64
[3] POLYMORPHIC DEBRISOQUIN METABOLISM IN A TURKISH POPULATION
BOZKURT, A
BASCI, NE
ISIMER, A
SAYAL, A
KAYAALP, SO
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (04) : 399 - 401
[4] DETERMINATION OF DEBRISOQUINE AND 4-HYDROXYDEBRISOQUINE IN URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION AFTER SOLID-PHASE EXTRACTION
BOZKURT, A
BASCI, NE
ISIMER, A
KAYAALP, SO
[J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1993, 11 (08) : 745 - 749
[5] BROSEN K, 1985, ACTA PHARMACOL TOX, V57, P357
[6] MEPHENYTOIN AND SPARTEINE OXIDATION - GENETIC POLYMORPHISMS IN DENMARK
DROHSE, A
BATHUM, L
BROSEN, K
GRAM, LF
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (05) : 620 - 625
[7] POLYMORPHIC OXIDATION OF SPARTEINE AND DEBRISOQUINE - RELATED PHARMACOGENETIC ENTITIES
EICHELBAUM, M
BERTILSSON, L
SAWE, J
ZEKORN, C
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (02) : 184 - 186
[8] A FAMILY AND POPULATION STUDY OF THE GENETIC-POLYMORPHISM OF DEBRISOQUINE OXIDATION IN A WHITE BRITISH-POPULATION
EVANS, DAP
MAHGOUB, A
SLOAN, TP
IDLE, JR
SMITH, RL
[J]. JOURNAL OF MEDICAL GENETICS, 1980, 17 (02) : 102 - 105
[9] THE GENETIC-CONTROL OF SPARTEINE AND DEBRISOQUINE METABOLISM IN MAN WITH NEW METHODS OF ANALYZING BIMODAL DISTRIBUTIONS
EVANS, DAP
HARMER, D
DOWNHAM, DY
WHIBLEY, EJ
IDLE, JR
RITCHIE, J
SMITH, RL
[J]. JOURNAL OF MEDICAL GENETICS, 1983, 20 (05) : 321 - 329
[10] CORRELATIONS AMONG THE METABOLIC RATIOS OF 3 TEST PROBES (METOPROLOL, DEBRISOQUINE AND SPARTEINE) FOR GENETICALLY-DETERMINED OXIDATION POLYMORPHISM IN A JAPANESE POPULATION
HORAI, Y
TAGA, J
ISHIZAKI, T
ISHIKAWA, K
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (01) : 111 - 115

← 1 2 →